Characterization of the interactions of potent allosteric inhibitors with glutaminase C, a key enzyme in cancer cell glutamine metabolism

Journal of Biological Chemistry

Volumn 293, Issue 10, 2018, Pages 3535-3545

  Huang, Qingqiu ^a   Stalnecker, Clint ^a,c   Zhang, Chengliang ^a   McDermott, Lee A ^b   Iyer, Prema ^b   O’Neill, Jason ^b   Reimer, Shawn ^b   Cerione, Richard A ^a   Katt, William P ^a  

^a Department of Obstetrics Gynecology   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; BINDING ENERGY; CELL ENGINEERING; CYTOLOGY; DISEASES; ENZYMES; METABOLISM; MOLECULES; SYNTHESIS (CHEMICAL);

ALLOSTERIC INHIBITOR; ALLOSTERIC MECHANISMS; ANTI-VASCULAR ENDOTHELIAL GROWTH FACTORS; BINDING AFFINITIES; ENZYMATIC ACTIVITIES; THERAPEUTIC TARGETS; TRIPLE-NEGATIVE BREAST CANCERS; X RAY CRYSTAL STRUCTURES;

CELLS;

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIS 2 (5 PHENYLACETAMIDO 1,2,4 THIADIAZOL 2 YL)ETHYL; CB 839; ENZYME INHIBITOR; GLUTAMINASE; GLUTAMINASE C; GLUTAMINE; UNCLASSIFIED DRUG; UPGL 00004; BENZENEACETAMIDE DERIVATIVE; BIS-2-(5-PHENYLACETAMIDO-1,2,4-THIADIAZOL-2-YL)ETHYL SULFIDE; CB-839; GLS1 PROTEIN, HUMAN; RECOMBINANT PROTEIN; SULFIDE; THIADIAZOLE DERIVATIVE; TUMOR PROTEIN;

ALLOSTERISM; AMINO ACID METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BINDING SITE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; DRUG POTENCY; DRUG PROTEIN BINDING; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC50; MOUSE; NONHUMAN; PRIORITY JOURNAL; X RAY CRYSTALLOGRAPHY; ALLOSTERIC SITE; AMINO ACID SUBSTITUTION; ANTAGONISTS AND INHIBITORS; BINDING COMPETITION; CELL PROLIFERATION; CHEMISTRY; CONFORMATION; DRUG EFFECT; DRUG RESISTANCE; GENETICS; HYDROGEN BOND; METABOLISM; MOLECULAR MODEL; MULTIDRUG RESISTANCE; MUTATION; PATHOLOGY; TRIPLE NEGATIVE BREAST CANCER; TUMOR CELL LINE;

ALLOSTERIC SITE; AMINO ACID SUBSTITUTION; ANTINEOPLASTIC AGENTS; BENZENEACETAMIDES; BINDING, COMPETITIVE; CELL LINE, TUMOR; CELL PROLIFERATION; CRYSTALLOGRAPHY, X-RAY; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; GLUTAMINASE; GLUTAMINE; HUMANS; HYDROGEN BONDING; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MUTATION; NEOPLASM PROTEINS; RECOMBINANT PROTEINS; SULFIDES; THIADIAZOLES; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 85043699777     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M117.810101     Document Type: Article

References (46)

1. DeBerardinis, R. J., and Cheng, T. (2010) Q’s next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 29, 313–324 CrossRef Medline
2. Gogvadze, V., Zhivotovsky, B., and Orrenius, S. (2010) The Warburg effect and mitochondrial stability in cancer cells. Mol. Aspects Med. 31, 60 –74 CrossRef Medline
3. Cairns, R. A., Harris, I. S., and Mak, T. W. (2011) Regulation of cancer cell metabolism. Nat. Rev. Cancer 11, 85–95 CrossRef Medline
4. Erickson, J. W., and Cerione, R. A. (2010) Glutaminase: a hot spot for regulation of cancer cell metabolism? Oncotarget 1, 734–740 CrossRef Medline
5. Dang, C. V. (2010) Rethinking the Warburg effect with Myc micromanaging glutamine metabolism. Cancer Res. 70, 859 – 862 CrossRef Medline
6. Matés, J. M., Segura, J. A., Martin-Rufián, M., Campos-Sandoval, J. A., Alonso, F. J., and Márquez, J. (2013) Glutaminase isoenzymes as key regulators in metabolic and oxidative stress against cancer. Curr. Mol. Med. 13, 514 –534 CrossRef Medline
7. Elgadi, K. M., Meguid, R. A., Qian, M., Souba, W. W., and Abcouwer, S. F. (1999) Cloning and analysis of unique human glutaminase isoforms generated by tissue-specific alternative splicing. Physiol. Genomics 1, 51– 62 CrossRef Medline
8. Lukey, M. J., Wilson, K. F., and Cerione, R. A. (2013) Therapeutic strategies impacting cancer cell glutamine metabolism. Future Med. Chem. 5, 1685–1700 CrossRef Medline
9. Wang, J. B., Erickson, J. W., Fuji, R., Ramachandran, S., Gao, P., Dinavahi, R., Wilson, K. F., Ambrosio, A. L., Dias, S. M., Dang, C. V., and Cerione, R. A. (2010) Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 18, 207–219 CrossRef Medline
10. Robinson, M. M., McBryant, S. J., Tsukamoto, T., Rojas, C., Ferraris, D. V., Hamilton, S. K., Hansen, J. C., and Curthoys, N. P. (2007) Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES). Biochem. J. 406, 407– 414 CrossRef Medline
11. Katt, W. P., Ramachandran, S., Erickson, J. W., and Cerione, R. A. (2012) Dibenzophenanthridines as inhibitors of glutaminase C and cancer cell proliferation. Mol. Cancer Ther. 11, 1269 –1278 CrossRef Medline
12. Shukla, K., Ferraris, D. V., Thomas, A. G., Stathis, M., Duvall, B., Delah-anty, G., Alt, J., Rais, R., Rojas, C., Gao, P., Xiang, Y., Dang, C. V., Slusher, B. S., and Tsukamoto, T. (2012) Design, synthesis, and pharmacological evaluation of bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors. J. Med. Chem. 55, 10551–10563 CrossRef Medline
13. Gross, M. I., Demo, S. D., Dennison, J. B., Chen, L., Chernov-Rogan, T., Goyal, B., Janes, J. R., Laidig, G. J., Lewis, E. R., Li, J., Mackinnon, A. L., Parlati, F., Rodriguez, M. L., Shwonek, P. J., Sjogren, E. B., et al. (2014) Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol. Cancer Ther. 13, 890 –901 CrossRef Medline
14. Srinivasan, M., Kalousek, F., and Curthoys, N. P. (1995) In vitro characterization of the mitochondrial processing and the potential function of the 68-kDa subunit of renal glutaminase. J. Biol. Chem. 270, 1185–1190 CrossRef Medline
15. Perera, S. Y., Chen, T. C., and Curthoys, N. P. (1990) Biosynthesis and processing of renal mitochondrial glutaminase in cultured proximal tubular epithelial cells and in isolated mitochondria. J. Biol. Chem. 265, 17764 –17770 Medline
16. Srinivasan, M., Kalousek, F., Farrell, L., and Curthoys, N. P. (1995) Role of the N-terminal 118 amino acids in the processing of the rat renal mitochondrial glutaminase precursor. J. Biol. Chem. 270, 1191–1197 CrossRef Medline
17. Holcomb, T., Taylor, L., Trohkimoinen, J., and Curthoys, N. P. (2000) Isolation, characterization and expression of a human brain mitochondrial glutaminase cDNA. Mol. Brain Res. 76, 56 – 63 CrossRef Medline
18. Morehouse, R. F., and Curthoys, N. P. (1981) Properties of rat renal phosphate-dependent glutaminase coupled to Sepharose: evidence that dimerization is essential for activation. Biochem. J. 193, 709 –716 CrossRef Medline
19. Stalnecker, C. A., Ulrich, S. M., Li, Y., Ramachandran, S., McBrayer, M. K., DeBerardinis, R. J., Cerione, R. A., and Erickson, J. W. (2015) Mechanism by which a recently discovered allosteric inhibitor blocks glutamine metabolism in transformed cells. Proc. Natl. Acad. Sci. U.S.A. 112, 394 –399 Medline
20. Li, Y., Erickson, J. W., Stalnecker, C. A., Katt, W. P., Huang, Q., Cerione, R. A., and Ramachandran, S. (2016) Mechanistic basis of glutaminase activation: a key enzyme that promotes glutamine metabolism in cancer cells. J. Biol. Chem. 291, 20900 –20910 CrossRef Medline
21. Pieter, A., van den Heuvel, A. P., Jing, J., Wooster, R. F., and Bachman, K. E. (2012) Analysis of glutamine dependency in non-small cell lung cancer GLS1 splice variant GAC is essential for cancer cell growth. Cancer Biol. Ther. 13, 1185–1194 CrossRef Medline
22. Le, A., Lane, A. N., Hamaker, M., Bose, S., Gouw, A., Barbi, J., Tsukamoto, T., Rojas, C. J., Slusher, B. S., Zhang, H., Zimmerman, L. J., Liebler, D. C., Slebos, R. J., Lorkiewicz, P. K., Higashi, R. M., Fan, T. W., and Dang, C. V. (2012) Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab. 15, 110 –121 CrossRef Medline
23. Seltzer, M. J., Bennett, B. D., Joshi, A. D., Gao, P., Thomas, A. G., Ferraris, D. V., Tsukamoto, T., Rojas, C. J., Slusher, B. S., Rabinowitz, J. D., Dang, C. V., and Riggins, G. J. (2010) Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res. 70, 8981– 8987 CrossRef Medline
24. Katt, W. P., Antonyak, M. A., and Cerione, R. A. (2015) Simultaneously targeting tissue transglutaminase and kidney type glutaminase sensitizes cancer cells to acid toxicity and offers new opportunities for therapeutic intervention. Mol. Pharm. 12, 46 –55 CrossRef Medline
25. DeLaBarre, B., Gross, S., Fang, C., Gao, Y., Jha, A., Jiang, F., Song, J. J., Wei, W., and Hurov, J. B. (2011) Full-length human glutaminase in complex with an allosteric inhibitor. Biochemistry 50, 10764 –10770 CrossRef Medline
26. Thangavelu, K., Pan, C. Q., Karlberg, T., Balaji, G., Uttamchandani, M., Suresh, V., Schüler, H., Low, B. C., and Sivaraman, J. (2012) Structural basis for the allosteric inhibitory mechanism of human kidney-type glutaminase (KGA) and its regulation by Raf-Mek-Erk signaling in cancer cell metabolism. Proc. Natl. Acad. Sci. U.S.A. 109, 7705–7710 CrossRef Medline
27. Ferreira, A. P., Cassago, A., Gonçalves Kde, A., Dias, M. M., Adamoski, D., Ascenção, C. F., Honorato, R. V., de Oliveira, J. F., Ferreira, I. M., Fornezari, C., Bettini, J., Oliveira, P. S., Paes Leme, A. F., Portugal, R. V., Ambrosio, A. L., and Dias, S. M. (2013) Active glutaminase C self-assembles into a supratetrameric oligomer that can be disrupted by an allosteric inhibitor. J. Biol. Chem. 288, 28009 –28020 CrossRef Medline
28. McDermott, L. A., Iyer, P., Vernetti, L., Rimer, S., Sun, J., Boby, M., Yang, T., Fioravanti, M., O’Neill, J., Wang, L., Drakes, D., Katt, W., Huang, Q., and Cerione, R. (2016) Design and evaluation of novel glutaminase inhibitors. Bioorg. Med. Chem. 24, 1819 –1839 CrossRef Medline
29. McDermott, L. A., Iyer, P. C., Cerione, R., and Katt, W. (April 7, 2016) Glutaminase inhibitors. U.S. Patent WO2016054388 A1
30. Stalnecker, C. A., Erickson, J. W., and Cerione, R. A. (2017) Conformational changes in the activation loop of mitochondrial glutaminase C: a direct fluorescence readout that distinguishes the binding of allosteric inhibitors from activators. J. Biol. Chem. 292, 6095–6107 CrossRef Medline
31. Ellis, L. M., and Hicklin, D. J. (2008) VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer 8, 579 –591 CrossRef Medline
32. Ferrara, N., and Kerbel, R. S. (2005) Angiogenesis as a therapeutic target. Nature 438, 967–974 CrossRef Medline
33. DeRose, Y. S., Wang, G., Lin, Y. C., Bernard, P. S., Buys, S. S., Ebbert, M. T., Factor, R., Matsen, C., Milash, B. A., Nelson, E., Neumayer, L., Randall, R. L., Stijleman, I. J., Welm, B. E., and Welm, A. L. (2011) Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat. Med. 17, 1514 –1520 CrossRef Medline
34. Feng, Q., Zhang, C., Lum, D., Druso, J. E., Blank, B., Wilson, K. F., Welm, A., Antonyak, M. A., and Cerione, R. A. (2017) A class of extracellular vesicles from breast cancer cells activates VEGF receptors and tumor angiogenesis. Nat. Commun. 8, 14450 CrossRef Medline
35. Huang, Q., Gruner, S. M., Kim, C. U., Mao, Y., Wu, X., and Szebenyi, D. M. (2016) Reduction of lattice disorder in protein crystals by high pressure cryocooling. J. Appl. Crystallogr. 49, 149 –157 CrossRef Medline
36. Englich, U., Kriksunov, I. A., Cerione, R. A., Cook, M. J., Gillilan, R., Gruner, S. M., Huang, Q., Kim, C. U., Miller, W., Nielsen, S., Schuller, D., Smith, S., and Szebenyi, D. M. (2011) Microcrystallography, high-pressure cryocooling and BioSAXS at MacCHESS. J. Synchrotron Radiat. 18, 70 –73 CrossRef Medline
37. Cassago, A., Ferreira, A. P., Ferreira, I. M., Fornezari, C., Gomes, E. R., Greene, K. S., Pereira, H. M., Garratt, R. C., Dias, S. M., and Ambrosio, A. L. (2012) Mitochondrial localization and structure-based phosphate activation mechanism of Glutaminase C with implications for cancer metabolism. Proc. Natl. Acad. Sci. U.S.A. 109, 1092–1097 CrossRef Medline
38. Berndt, K. D., Beunink, J., Schröder, W., and Wüthrich, K. (1993) Designed replacement of an internal hydration water molecule in BPTI: structural and functional implications of a glycine-to-serine mutation. Biochemistry 32, 4564 – 4570 CrossRef Medline
39. DeLano, W. L. (2010) The PyMOL Molecular Graphics System, version 1.3 r1, Schroedinger, LLC, New York
40. Lukey, M. J., Greene, K. S., Erickson, J. W., Wilson, K. F., and Cerione, R. A. (2016) The oncogenic transcription factor c-Jun regulates glutaminase expression and sensitizes cells to glutaminase-targeted therapy. Nat. Commun. 7, 11321 CrossRef Medline
41. Ramachandran, S., Pan, C. Q., Zimmermann, S. C., Duvall, B., Tsukamoto, T., Low, B. C., and Sivaraman, J. (2016) Structural basis for exploring the allosteric inhibition of human kidney type glutaminase. Oncotarget 7, 57943–57954 CrossRef Medline
42. Li, J., Chen, L., Goyal, B., Laidig, G., Stanton, T. F., and Sjogren, E. B. (December 10, 2013) Heterocyclic inhibitors of glutaminase. U. S. Patent US8604016 B2
43. Otwinowski, Z., and Minor, W. (1997) Processing of x-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307–326 CrossRef Medline
44. McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Sto-roni, L. C., and Read, R. J. (2007) Phaser crystallographic software. J. Appl. Crystallogr. 40, 658 – 674 CrossRef Medline
45. Emsley, P., and Cowtan, K. (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126 –2132 CrossRef Medline
46. Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L. W., Kapral, G. J., Grosse-Kunstleve, R. W., McCoy, A. J., Moriarty, N. W., Oeffner, R., Read, R. J., Richardson, D. C., Richardson, J. S., Terwilliger, T. C., and Zwart, P. H. (2010) PHENIX: A comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213–221 CrossRef Medline